Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1755-8794
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation ; volume:15 ; number:1 ; day:19 ; month:2 ; year:2022 ; pages:1-7 ; date:12.2022
BMC medical genomics ; 15, Heft 1 (19.2.2022), 1-7, 12.2022
- Creator
-
Baba, Yuto
Kosaka, Takeo
Kobayashi, Hiroaki
Nakamura, Kohei
Mikami, Shuji
Nishihara, Hiroshi
Nakanishi, Makoto
Oya, Mototsugu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12920-022-01178-z
- URN
-
urn:nbn:de:101:1-2022052220430559846000
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Baba, Yuto
- Kosaka, Takeo
- Kobayashi, Hiroaki
- Nakamura, Kohei
- Mikami, Shuji
- Nishihara, Hiroshi
- Nakanishi, Makoto
- Oya, Mototsugu
- SpringerLink (Online service)
Other Objects (12)
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
Effect of simvastatin on castration-resistant prostate cancer cells